Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
Therapie
|
June 22, 2007
[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)]
Catherine Delbaldo
Therapeutic Advances in Medical Oncology
|
January 10, 2012
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential
Catherine Delbaldo, Sandrine Faivre, Chantal Dreyer, et al.
Presse Medicale (Paris, France : 1983)
|
August 1, 2002
[New drugs in bronchial cancer]
Catherine Delbaldo, Sandrine Faivre, Christian Monnerat, et al.
La Revue Du Praticien
|
May 26, 2009
[Management of biliary tract carcinomas]
Catherine Delbaldo, Alexis Laurent, Julien Grenier, et al.
Anti-Cancer Drugs
|
August 4, 2015
Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy
Cédric Chanat, Catherine Delbaldo, Jennifer Denis, et al.
Targeted Oncology
|
May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
JAMA
|
July 29, 2004
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis
Catherine Delbaldo, Stefan Michiels, Nathalie Syz, et al.
Anticancer Research
|
September 21, 2012
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series
Stéphane Culine, Zineb Sellam, Linda Bouaita, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development
Marie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
Investigational New Drugs
|
September 19, 2007
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors
Catherine Delbaldo, Eric Raymond, Karina Vera, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
Therapie
|
June 22, 2007
[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)]
Catherine Delbaldo
Therapeutic Advances in Medical Oncology
|
January 10, 2012
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential
Catherine Delbaldo, Sandrine Faivre, Chantal Dreyer, et al.
Presse Medicale (Paris, France : 1983)
|
August 1, 2002
[New drugs in bronchial cancer]
Catherine Delbaldo, Sandrine Faivre, Christian Monnerat, et al.
La Revue Du Praticien
|
May 26, 2009
[Management of biliary tract carcinomas]
Catherine Delbaldo, Alexis Laurent, Julien Grenier, et al.
Anti-Cancer Drugs
|
August 4, 2015
Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy
Cédric Chanat, Catherine Delbaldo, Jennifer Denis, et al.
Targeted Oncology
|
May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
JAMA
|
July 29, 2004
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis
Catherine Delbaldo, Stefan Michiels, Nathalie Syz, et al.
Anticancer Research
|
September 21, 2012
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series
Stéphane Culine, Zineb Sellam, Linda Bouaita, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development
Marie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
Investigational New Drugs
|
September 19, 2007
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors
Catherine Delbaldo, Eric Raymond, Karina Vera, et al.
Page
of 3